May 21 () - Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another ‌part ...

Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...

Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory ...

After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...

For the second time in as many weeks, there is promising news from the race for a COVID-19 vaccine as infections surge across the United States and Europe. US biotech firm Moderna Inc on Monday said ...

Will a hantavirus outbreak offset the regulatory risks weighing on Moderna stock? The path to recovery is far from certain.

Presented by Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Moderna’s mRNA flu shot to get FDA review After some initial ...

Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and ...

Moderna’s mRNA flu vaccine gave more protection against illness than the standard flu shot in a phase 3 clinical trial, according to published results.

The company confirmed early-stage hantavirus research as a WHO-confirmed outbreak grows, while flu vaccine data published in ...

Moderna shares jump as it reveals it has been researching vaccines against hantaviruses - The hantavirus outbreak on the MV ...

Moderna’s experimental mRNA flu shot will be reviewed by a Food and Drug Administration advisory panel next month, a move ...